Risk of dipeptidyl peptidase‐4 (DPP‐4) inhibitors on site‐specific cancer: A systematic review and meta‐analysis

The long‐term impact of dipeptidyl peptidase‐4 (DPP‐4) inhibition is unknown, and there are concerns about the influence of DPP‐4 inhibition on carcinogenesis of the pancreas and thyroid. As DPP‐4 is a rather unselective enzyme present in many tissues, we focused on all specific cancer types. PubMed and EMBASE were searched between January 2005 and April 2017 to identify studies comparing DPP‐4 inhibitors with either placebo or active drugs on cancer risk. Studies were included if they reported on at least one specific cancer outcome and had a follow‐up of at least 1 year after start of drug use. Methodological quality of the studies was assessed by the Cochrane Collaboration's tool and the Newcastle‐Ottawa Scale. Twenty‐five studies met the inclusion criteria (12 randomized controlled trials and 13 observational studies). Sample sizes of the DPP‐4 inhibitor groups ranged from 29 to 8212 patients for randomized controlled trials and from 2422 to 71 137 patients for observational studies. Mean age ranged from 51 to 76 years, and mean follow‐up was 1.5 years. None of the pooled (sensitivity) analyses, except the observational studies studying breast cancer (hazard ratio [95% CI]: 0.76 [0.60‐0.96]), showed evidence for an association between DPP‐4 inhibitors and site‐specific cancer. Also for pancreatic and thyroid cancer, no statistically significant risk was found. Based on the current literature, it is not possible to conclude whether DPP‐4 inhibitors were associated with an increased risk of site‐specific cancer. Future studies should address the methodological limitations and follow patients for a longer period to determine the long‐term cancer risk of DPP‐4 inhibitors.

[1]  S. Zhan,et al.  Incretin‐based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials , 2018, Diabetes, obesity & metabolism.

[2]  G. Nijpels,et al.  Risk of Dipeptidyl-Peptidase-4 (Dpp-4) Inhibitors On Site-Specific Cancer: A Systematic Review And Meta-Analysis , 2017 .

[3]  C. Tseng Sitagliptin May Reduce Breast Cancer Risk in Women With Type 2 Diabetes , 2017, Clinical breast cancer.

[4]  C. Tseng Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes , 2016, Oncotarget.

[5]  R. Platt,et al.  Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink , 2016, British Medical Journal.

[6]  Guoxin Zhang,et al.  Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials , 2016, Diabetes Therapy.

[7]  Phyo T. Htoo,et al.  Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors , 2016, European Journal of Clinical Pharmacology.

[8]  C. Tseng Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes , 2016, Oncotarget.

[9]  H. Yamada,et al.  Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model , 2016, PeerJ.

[10]  H. Leufkens,et al.  Use of incretin agents and risk of pancreatic cancer: a population‐based cohort study , 2016, Diabetes, obesity & metabolism.

[11]  D. Juurlink,et al.  Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study , 2016, British Medical Journal.

[12]  Deepak L. Bhatt,et al.  Frequency of cancer events with saxagliptin in the SAVOR‐TIMI 53 trial , 2016, Diabetes, obesity & metabolism.

[13]  C. Tseng Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes , 2016, European journal of clinical investigation.

[14]  M. Pencina,et al.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.

[15]  L. Niskanen,et al.  Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION) , 2015, Diabetes, obesity & metabolism.

[16]  Weiqing Wang,et al.  Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24-week, randomized, clinical trial , 2015, Journal of diabetes investigation.

[17]  C. Tseng,et al.  An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers , 2015, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[18]  M. Zeegers,et al.  Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients. , 2015, British journal of clinical pharmacology.

[19]  J. Buse,et al.  Dipeptidyl‐peptidase‐4 inhibitors and pancreatic cancer: a cohort study , 2014, Diabetes, obesity & metabolism.

[20]  L. Pani,et al.  Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[21]  H. Woerle,et al.  Safety and efficacy of the dipeptidyl peptidase‐4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years , 2014, Diabetes, obesity & metabolism.

[22]  B. Göke,et al.  Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas? , 2014, Expert opinion on drug safety.

[23]  A. Araujo,et al.  Incretin-mimetic therapies and pancreatic disease: a review of observational data , 2014, Current medical research and opinion.

[24]  Lawrence A Leiter,et al.  Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study , 2014, Diabetes Care.

[25]  G. Umpierrez,et al.  Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5) , 2014, Diabetes Care.

[26]  M. Bajaj,et al.  Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study , 2014, Diabetic medicine : a journal of the British Diabetic Association.

[27]  M. Feinglos,et al.  HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin , 2014, Diabetes Care.

[28]  B. Hummer,et al.  Pancreatic safety of incretin-based drugs--FDA and EMA assessment. , 2014, The New England journal of medicine.

[29]  K. Chan,et al.  A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs , 2013, Diabetes, obesity & metabolism.

[30]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[31]  D. Giugliano,et al.  Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin , 2013, Drug design, development and therapy.

[32]  R. Elashoff,et al.  A Critical Analysis of the Clinical Use of Incretin-Based Therapies , 2013, Diabetes Care.

[33]  M. Marre,et al.  Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency , 2013, Diabetes Care.

[34]  N. Tajima,et al.  Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks , 2012, Journal of diabetes investigation.

[35]  A. Barnett,et al.  Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18‐week randomized, double‐blind, placebo‐controlled phase III trial with a 34‐week active‐controlled extension , 2012, Diabetes, obesity & metabolism.

[36]  C. Alves,et al.  A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. , 2012, Diabetes research and clinical practice.

[37]  Y. Seino,et al.  Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study , 2012, Journal of diabetes investigation.

[38]  David R Owens,et al.  Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial , 2012, The Lancet.

[39]  G. Nijpels,et al.  Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well‐controlled type 2 diabetes patients * , 2012, Journal of diabetes.

[40]  B. Carstensen,et al.  Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence , 2012, Diabetologia.

[41]  K. Richardson,et al.  Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias , 2011, Diabetologia.

[42]  R. Elashoff,et al.  Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. , 2011, Gastroenterology.

[43]  R. Cuddihy,et al.  One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial , 2011, International journal of clinical practice.

[44]  J. Higgins Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[45]  Jeffrey A. Johnson,et al.  Diabetes, Insulin Use, and Cancer Risk: Are Observational Studies Part of the Solution–or Part of the Problem? , 2010, Diabetes.

[46]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[47]  Mitsutoshi Kato,et al.  Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. , 2009, Diabetes research and clinical practice.

[48]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[49]  S. Friberg,et al.  On the growth rates of human malignant tumors: Implications for medical decision making , 1997, Journal of surgical oncology.

[50]  K. Rothman Induction and latent periods. , 1981, American journal of epidemiology.